Last Updated : August 19, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
Therapeutic Area: Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
Therapeutic Area: Paroxysmal nocturnal hemoglobinuria (PNH)
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
Therapeutic Area: acne vulgaris
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
Therapeutic Area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
Therapeutic Area: Acute myeloid leukemia (AML)
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
Therapeutic Area: Adjuvant treatment of HR-positive, HER2-negative early breast cancer
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
Therapeutic Area: Non-small cell lung cancer
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation